Top

Open Access 27-03-2024 | Positron Emission Tomography | Original Article

18F-FDG PET/CT metabolism multi-parameter prediction of chemotherapy efficacy in locally progressive gastric cancer

Authors: Luqiang Jin, Linghe Zhang, Liping Fu, Fahuan Song, Aiping Cheng

Published in: Annals of Nuclear Medicine

Abstract

Purpose

This study aimed to use an ¹⁸F-FDG PET/CT multiparametric quantitative analysis to determine the efficacy of neoadjuvant chemotherapy in patients with locally progressive gastric cancer.

Materials and methods

We conducted a retrospective analysis of 34 patients with pathologically identified gastric cancer who received neoadjuvant chemotherapy and surgery. Chemotherapy regimens were followed and ¹⁸F-FDG PET/CT was conducted. We ascertained multiparamaters of the target lesions pre- and post-treatment and determined the ideal cutoff values for the percentage change in biomarkers. Independent factors were evaluated using binary logistic regression. A response classification system was used to explore the association between metabolic and anatomical responses and the degree of pathological remission.

Results

Binary logistic regression analysis showed that Lauren bowel type and change in total lesion glycolysis >45.2% were risk predictors for the efficacy of neoadjuvant chemotherapy; total lesion glycolysis demonstrated the best predictive efficacy. The categorical variable system of the two-module response (metabolic and anatomical response) group had a higher predictive accuracy than that of the single-module response (metabolic or anatomical response) group.

Conclusions

Using ¹⁸F-FDG PET/CT multiparametric quantitative analysis, Lauren bowel type and change in total lesion glycolysis >45.2% were independent predictors of the efficacy of neoadjuvant chemotherapy in patients with gastric adenocarcinoma. Additionally, the dual-module assessment demonstrated high predictive efficacy.

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33. https://doi.org/10.3322/caac.21708.CrossRefPubMed

Xia C, Dong X, Li H, Cao M, Sun D, He S, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022;135:584–90. https://doi.org/10.1097/CM9.0000000000002108.CrossRefPubMed

Ajani JA, D’Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, et al. Gastric cancer, version 22022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20:167–92. https://doi.org/10.6004/jnccn.2022.0008.CrossRefPubMed

Anderson E, LeVee A, Kim S, Atkins K, Guan M, Placencio-Hickok V, et al. A comparison of clinicopathologic outcomes across neoadjuvant and adjuvant treatment modalities in resectable gastric cancer. JAMA Netw Open. 2021;4: e2138432. https://doi.org/10.1001/jamanetworkopen.2021.38432.CrossRefPubMedPubMedCentral

Lin JX, Tang YH, Lin GJ, Ma YB, Desiderio J, Li P, et al. Association of adjuvant chemotherapy with overall survival among patients with locally advanced gastric cancer after neoadjuvant chemotherapy. JAMA Netw Open. 2022;5: e225557. https://doi.org/10.1001/jamanetworkopen.2022.5557.CrossRefPubMedPubMedCentral

Kang YK, Yook JH, Park YK, Lee JS, Kim YW, Kim JY, et al. PRODIGY: A phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer. J Clin Oncol. 2021;39:2903–13. https://doi.org/10.1200/JCO.20.02914.CrossRefPubMedPubMedCentral

Su J, Guo W, Chen Z, Wang L, Liu H, Zhao L, et al. Safety and short-term outcomes of laparoscopic surgery for advanced gastric cancer after neoadjuvant immunotherapy: a retrospective cohort study. Front Immunol. 2022;13:1078196. https://doi.org/10.3389/fimmu.2022.1078196.CrossRefPubMedPubMedCentral

Song Z, Zou S, Zhou W, Huang Y, Shao L, Yuan J, et al. Clinically applicable histopathological diagnosis system for gastric cancer detection using deep learning. Nat Commun. 2020;11:4294. https://doi.org/10.1038/s41467-020-18147-8.CrossRefPubMedPubMedCentral

Abdelrahman AM, Goenka AH, Alva-Ruiz R, Yonkus JA, Leiting JL, Graham RP, et al. FDG-PET predicts neoadjuvant therapy response and survival in borderline resectable/locally advanced pancreatic adenocarcinoma. J Natl Compr Canc Netw. 2022;20:1023-1032.e3. https://doi.org/10.6004/jnccn.2022.7041.CrossRefPubMed

10.

van der Hiel B, Blankenstein SA, Aalbersberg EA, Wondergem M, Stokkel MPM, van de Wiel BA, et al. ¹⁸F-FDG PET/CT during neoadjuvant targeted therapy in prior unresectable stage III melanoma patients: can (early) metabolic imaging predict histopathologic response or recurrence? Clin Nucl Med. 2022;47:583–9. https://doi.org/10.1097/RLU.0000000000004217.CrossRefPubMed

11.

Lim CH, Park YJ, Shin M, Cho YS, Choi JY, Lee KH, et al. Tumor SUVs on ¹⁸F-FDG PET/CT and aggressive pathological features in esophageal squamous cell carcinoma. Clin Nucl Med. 2020;45:e128–33. https://doi.org/10.1097/RLU.0000000000002926.CrossRefPubMed

12.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. https://doi.org/10.1016/j.ejca.2008.10.026.CrossRefPubMed

13.

Hall WA, Li J, You YN, Gollub MJ, Grajo JR, Rosen M, et al. Prospective correlation of magnetic resonance tumor regression grade with pathologic outcomes in total neoadjuvant therapy for rectal adenocarcinoma. J Clin Oncol. 2023;41:4643–51. https://doi.org/10.1200/JCO.22.02525.CrossRefPubMed

14.

Sánchez-Izquierdo N, Perlaza P, Pagès M, Buxó E, Rios J, Rubello D, et al. Assessment of response to neoadjuvant chemoradiotherapy by ¹⁸F-FDG PET/CT in patients with locally advanced esophagogastric junction adenocarcinoma. Clin Nucl Med. 2020;45:38–43. https://doi.org/10.1097/RLU.0000000000002840.CrossRefPubMed

15.

Moore JL, Subesinghe M, Santaolalla A, Green M, Deere H, Van Hemelrijck M, et al. Metabolic tumour and nodal response to neoadjuvant chemotherapy on FDG PET-CT as a predictor of pathological response and survival in patients with oesophageal adenocarcinoma. Eur Radiol. 2023;33:3647–59. https://doi.org/10.1007/s00330-023-09482-7.CrossRefPubMedPubMedCentral

16.

Nose Y, Makino T, Tatsumi M, Tanaka K, Yamashita K, Noma T, et al. Risk stratification of oesophageal squamous cell carcinoma using change in total lesion glycolysis and number of PET-positive lymph nodes. Br J Cancer. 2023;128:1879–87. https://doi.org/10.1038/s41416-023-02151-y.CrossRefPubMedPubMedCentral

17.

Güç ZG, Turgut B, Avci A, Cengiz F, Eren Kalender M, Alacacioğlu A. Predicting pathological response and overall survival in locally advanced gastric cancer patients undergoing neoadjuvant chemotherapy: the role of PET/computed tomography. Nucl Med Commun. 2022;43:560–7. https://doi.org/10.1097/MNM.0000000000001534.CrossRefPubMed

18.

Beer L, Hochmair M, Haug AR, Schwabel B, Kifjak D, Wadsak W, et al. Comparison of RECIST, iRECIST, and PERCIST for the evaluation of response to PD-1/PD-L1 blockade therapy in patients with non-small cell lung cancer. Clin Nucl Med. 2019;44:535–43. https://doi.org/10.1097/RLU.0000000000002603.CrossRefPubMed

19.

Velez EM, Desai B, Ji L, Quinn DI, Colletti PM, Jadvar H. Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria. Theranostics. 2020;10:3254–62. https://doi.org/10.7150/thno.39838.CrossRefPubMedPubMedCentral

20.

Benz MR, Armstrong WR, Ceci F, Polverari G, Donahue TR, Wainberg ZA, et al. ¹⁸F-FDG PET/CT Imaging biomarkers for early and late evaluation of response to first-line chemotherapy in patients with pancreatic ductal adenocarcinoma. J Nucl Med. 2022;63:199–204. https://doi.org/10.2967/jnumed.121.261952.CrossRefPubMed

21.

Dalah E, Tai A, Oshima K, Hall WA, Erickson B, Li XA. PET-based treatment response assessment for neoadjuvant chemoradiation in pancreatic adenocarcinoma: an exploratory study. Transl Oncol. 2018;11:1104–9. https://doi.org/10.1016/j.tranon.2018.06.011.CrossRefPubMedPubMedCentral

22.

Tang L, Wang XJ, Baba H, Giganti F. Gastric cancer and image-derived quantitative parameters: Part 2-a critical review of DCE-MRI and ¹⁸F-FDG PET/CT findings. Eur Radiol. 2020;30:247–60. https://doi.org/10.1007/s00330-019-06370-x.CrossRefPubMed

23.

Sah BK, Zhang B, Zhang H, Li J, Yuan F, Ma T, et al. Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer. Nat Commun. 2020;11:6093. https://doi.org/10.1038/s41467-020-19965-6.CrossRefPubMedPubMedCentral

Title: 18F-FDG PET/CT metabolism multi-parameter prediction of chemotherapy efficacy in locally progressive gastric cancer
Authors: Luqiang Jin
Linghe Zhang
Liping Fu
Fahuan Song
Aiping Cheng
Publication date: 27-03-2024
Publisher: Springer Nature Singapore
Keywords: Positron Emission Tomography
Computed Tomography
Computed Tomography
Cytostatic Therapy
Gastric Cancer
Gastric Cancer
Published in: Annals of Nuclear Medicine
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-024-01921-9

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

18F-FDG PET/CT metabolism multi-parameter prediction of chemotherapy efficacy in locally progressive gastric cancer

Abstract

Purpose

Materials and methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Materials and methods

Results

Conclusions

Please log in to get access to this content